A new report by analytics company GlobalData has found that the global pharmaceutical market for age-related macular degeneration (AMD) is expected to double in size by 2028.
The company shared that the AMD market was worth $8.6bn in nine countries, including the US, France and the UK, and is expected to grow to $18.7bn by 2028.
GlobalData explained that growth in the market will be driven by the entry of longer acting anti-angiogenic therapies and the launch of products for dry AMD and geographic atrophy.
Magdalene Crabbe, pharma analyst at GlobalData, said: ‘The unmet needs in the AMD market are set to be addressed in the coming years, as frequent intravitreal injections to treat wet AMD have become burdensome for patients who live in rural areas or have mobility issues.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
